You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Lymphoma, T-Cell, Peripheral

Showing 51 - 75 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Peripheral T Cell Lymphoma Trial in Zhejiang (Mitoxantrone liposome?Chidamide?Azacitidine)

Recruiting
  • Peripheral T Cell Lymphoma
  • Mitoxantrone liposome态Chidamide态Azacitidine
  • Zhejiang, Zhejiang, China
    Second Affiliated Hospital, School of Medicine, Zhejiang Univers
Aug 9, 2022

Cutaneous T Cell Lymphoma, Mycosis Fungoides Trial (Hypericin, Visible Light)

Not yet recruiting
  • Cutaneous T Cell Lymphoma
  • Mycosis Fungoides
  • (no location specified)
May 23, 2023

NK/T Cell Lymphoma, Vascular Immunomother T Cell Lymphoma, Non-Hodgkin Lymphoma Trial in Guangzhou (GNC-038)

Not yet recruiting
  • NK/T Cell Lymphoma
  • +2 more
  • Guangzhou, Guangdong, China
  • +1 more
Jan 12, 2023

Folliculotropic Mycosis Fungoides, Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent Mycosis Fungoides Trial in United

Recruiting
  • Folliculotropic Mycosis Fungoides
  • +7 more
  • Durvalumab
  • +2 more
  • Duarte, California
  • +3 more
Jan 12, 2023

Cutaneous T-cell Lymphoma Retreated With Brentuximab Vedotin

Not yet recruiting
  • T-Cell Lymphoma
  • No intervention
  • Bordeaux, France
  • +10 more
May 24, 2023

Cutaneous T Cell Lymphoma Trial in Chicago (APR-TD011 (RLF-TD011))

Not yet recruiting
  • Cutaneous T Cell Lymphoma
  • APR-TD011 (RLF-TD011)
  • Chicago, Illinois
    Dermatology CTU
Feb 6, 2023

Peripheral T Cell Lymphoma (PTCL), Cell Therapy Trial in United States (MT-101, MT-101 + Conditioning (Lymphodepleting)

Recruiting
  • Lymphoma, T-Cell, Peripheral
  • +4 more
  • MT-101
  • MT-101 + Conditioning (Lymphodepleting) Chemotherapy
  • Duarte, California
  • +8 more
Jan 27, 2023

T-cell Lymphoma, Relapsed and Refractory T-cell Lymphoma Trial in New York, Columbus (Ibrutinib)

Active, not recruiting
  • T-cell Lymphoma
  • Relapsed and Refractory T-cell Lymphoma
  • New York, New York
  • +1 more
Nov 8, 2022

T-cell Non-Hodgkin Lymphoma Trial in Boston (Cyclophosphamide, Doxorubicin, Vincristine)

Terminated
Has Results
  • T-cell Non-Hodgkin Lymphoma
  • Boston, Massachusetts
  • +1 more
Jan 26, 2023

Advanced Cancer, Follicular Lymphoma, Peripheral T Cell Lymphoma Trial (BR1733)

Not yet recruiting
  • Advanced Cancer
  • +3 more
  • (no location specified)
Feb 27, 2023

T-Cell Lymphoma Trial (Brentuximab vedotin, Pembrolizumab)

Not yet recruiting
  • T-Cell Lymphoma
  • (no location specified)
Jul 22, 2022

T Lymphoblastic Leukemia/Lymphoma, T-cell Acute Lymphoblastic Leukemia, Peripheral T Cell Lymphoma Trial in Shanghai (anti-CD7

Recruiting
  • T Lymphoblastic Leukemia/Lymphoma
  • +4 more
  • anti-CD7 CAR-T cells
  • Shanghai, China
    Xianmin General Song
Aug 29, 2022

T-Cell Non-Hodgkin Lymphoma, Acute Myeloid Leukemia, Angioimmunoblastic T-cell Lymphoma Trial in Saint Louis (WU-CART-007)

Not yet recruiting
  • T-Cell Non-Hodgkin Lymphoma
  • +14 more
  • WU-CART-007
  • Saint Louis, Missouri
    Washington University School of Medicine
Jan 17, 2023

Relapsed/Refractory Peripheral T-cell Lymphoma Trial in Fairport (Tolinapant, Decitabine + Cedazuridine)

Recruiting
  • Relapsed/Refractory Peripheral T-cell Lymphoma
  • Aurora, Colorado
  • +2 more
Jan 3, 2023

Extranodal NK/T Cell Lymphoma, Nasal Type Trial in Guangdong (IBI318(Recombinant human anti-PD1/PD-L1 bispecific antibody))

Active, not recruiting
  • Extranodal NK/T Cell Lymphoma, Nasal Type
  • IBI318(Recombinant human anti-PD1/PD-L1 bispecific antibody)
  • Guangdong, China
    Sun Yat-sen University Cancer Center
Oct 10, 2022

T-Cell Lymphoma Trial in Saint Louis (Duvelisib, Peripheral blood draw)

Recruiting
  • T-Cell Lymphoma
  • Saint Louis, Missouri
    Washington University School of Medicine
Jul 18, 2022

T Cell Lymphoma Trial in Shanghai (Chidamide combined with BEAM)

Recruiting
  • T Cell Lymphoma
  • Chidamide combined with BEAM
  • Shanghai, Shanghai, China
    Ruijin Hospital
Sep 27, 2022

Treatment, Peripheral T-cell Lymphoma Trial in Beijing (liposomal mitoxantrone HCl, gemcitabine, dexamethasone, and cisplatin)

Recruiting
  • Treatment
  • Peripheral T-cell Lymphoma
  • liposomal mitoxantrone hydrochloride, gemcitabine, dexamethasone, and cisplatin
  • Beijing, China
  • +4 more
Jun 28, 2022

Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Enteropathy-Associated T-Cell Lymphoma, Recurrent Follicular T-Cell

Recruiting
  • Recurrent Angioimmunoblastic T-Cell Lymphoma
  • +13 more
  • Brentuximab Vedotin
  • Pembrolizumab
  • Chicago, Illinois
    Northwestern University
Jun 15, 2022

Venetoclax Tablets Crushed and Dissolved Into a Solution

Not yet recruiting
  • Hematologic Malignancy
  • +18 more
  • 1. Drug: The Venetoclax PK study is collecting bodily fluid samples (ie., whole blood and optional cerebrospinal fluid) of patients prescribed venetoclax as crushed tablets per standard of care.
  • Cincinnati, Ohio
    Cincinnati Children's Hospital Medical Center
Nov 8, 2023

Cutaneous T Cell Lymphoma, Mycosis Fungoides Trial (Mogamulizumab, Brentuximab vedotin)

Not yet recruiting
  • Cutaneous T Cell Lymphoma
  • Mycosis Fungoides
  • (no location specified)
Dec 7, 2022

Newly Diagnosed Peripheral T-cell Lymphoma Trial in Nanjing (C-BEAM Regimen, BEAM Regimen)

Recruiting
  • Newly Diagnosed Peripheral T-cell Lymphoma
  • C-BEAM Regimen
  • BEAM Regimen
  • Nanjing, Jiangsu, China
    Hematological Department, People's Hospital of Jiangsu Province
Jun 27, 2023

T-Cell Lymphoma Relapsed, T-Cell Lymphoma Refractory Trial in Italy (Venetoclax)

Active, not recruiting
  • T-Cell Lymphoma Relapsed
  • T-Cell Lymphoma Refractory
  • Aviano, Italy
  • +12 more
Dec 20, 2022

T-Cell Lymphoma Trial (Brentuximab vedotin)

Not yet recruiting
  • T-Cell Lymphoma
  • Brentuximab vedotin
  • (no location specified)
Jun 30, 2022

Anaplastic Large Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype, Recurrent Anaplastic Large Cell Lymphoma

Recruiting
  • Anaplastic Large Cell Lymphoma
  • +19 more
  • Duarte, California
  • +2 more
Aug 15, 2022